XenaCare Holdings` Pain Reliever, Cobroxin, Wins "Best New Product" Award at the Efficient Collaborative Retail Marketing (ECRM) Conference

Attendees of the Recent Efficient Collaborative Retail Marketing (ECRM)
Conference, Including Representatives from Many of the Major National Retailers,
Have Selected XenaCare Holdings` Pain Reliever, Cobroxin, as the Winner in the
Category for "Best New Product."
DELRAY BEACH, Fla.--(Business Wire)--
XenaCare Holdings, Inc. (OTCBB: XCHO), a company specializing in the marketing
and retail distribution of consumer healthcare products has announced today that
its stage 2 pain reliever, Cobroxin, has won the award for "Best New Product" at
the recent Efficient Collaborative Retail Marketing (ECRM) Conference held in
Miami, Florida.

"It is an honor to have Cobroxin chosen as the best new product at ECRM,"
commented Frank Rizzo, President of XenaCare Holdings, Inc. "This award, which
was selected by fellow conference attendees, including representatives from many
of the major national retailers, supports our belief that Cobroxin will soon
become the preferred alternative to current opiate and acetaminophen-based
analgesics," he concluded.

Cobroxin is thefirstopiate and acetaminophen-free pain relieveravailable as an
over-the-counter formulation clinically proven to treat moderate to severe
(Stage 2) pain. Recently, XenaCare Holdings was awarded the exclusive license
for marketing and distributing Cobroxin within the United States.

As an added prize for winning the award, XenaCare Holdings will also receive a
full page advertisement in an upcoming issue of Drug Store News, a placement
reaching over 31,000 subscribers.

About XenaCare Holdings

XenaCare Holdings, Inc. engages in the formulation, marketing, and distribution
of nutrition supplement products primarily in the United States. Its clinical
products include XenaCor, which lowers serum cholesterol, C-reactive protein,
and homocysteine levels to support cardiovascular health; XenaTri for lowering
triglycerides and raising HDL to support cardiovascular health; and XenaZyme
Plus that increases the body`s oxygen carrying capacities designed to support
digestion. XenaCare`s clinical products also comprise body replenishment
products. In addition, the company offers formulations for the lifestyle
performance market, which consists of sports line for athletes, including
SunPill that is formulated to protect the skin when exposed to damaging
ultraviolet rays. XenaCare markets its products through the Internet,
pharmacies, and doctors offices. The company was founded in 2001 and is based in
Delray Beach, Florida.

http://www.XenaCareHoldings.com

http://www.Cobroxin.com

SEC Disclaimer

This press release contains forward-looking statements. The words or phrases
"would be," "will allow," "intends to," "will likely result," "are expected to,"
"will continue," "is anticipated," "estimate," "project," or similar expressions
are intended to identify "forward-looking statements." Actual results could
differ materially from those projected in XenaCare's ("the Company") business
plan. The Company's business is subject to various risks, which are discussed in
the Company's filings with the Securities and Exchange Commission ("SEC").The
award given to XenaCare at ECRM should not be construed as an indication in any
way whatsoever of the value of the Company or its common stock.The Company's
filings may be accessed at the SEC's Edgar system at www.sec.gov.Statements made
herein are as of the date of this press release and should not be relied upon as
of any subsequent date. The Company cautions readers not to place reliance on
such statements. Unless otherwise required by applicable law, we do not
undertake, and we specifically disclaim any obligation, to update any
forward-looking statements to reflect occurrences, developments, unanticipated
events or circumstances after the date of such statement.

XenaCare Holdings
Frank Rizzo, 561-496-6676
FRizzo@XenaCare.com

Copyright Business Wire 2009